Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone

Aahd Kubbara; William H Amundson; Adam Herman; Adam M Lee; Jeffrey R Bishop; Hyun Joo Kim

doi:10.1016/j.heliyon.2023.e18573

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone

Heliyon. 2023 Jul 24;9(8):e18573. doi: 10.1016/j.heliyon.2023.e18573. eCollection 2023 Aug.

Authors

Aahd Kubbara¹, William H Amundson², Adam Herman³, Adam M Lee⁴, Jeffrey R Bishop⁴, Hyun Joo Kim¹

Affiliations

¹ Department of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep, University of Minnesota, Minneapolis, United States.
² Pulmonary and Critical Care Medicine, Regions Hospital, University of Minnesota, St. Paul, Minneapolis, MN, United States.
³ University of Minnesota, Supercomputing Institute, Minneapolis, United States.
⁴ Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, United States.

Abstract

Background: Genetic variations in Idiopathic Pulmonary Fibrosis (IPF) affect survival and outcomes. Current antifibrotic agents are managed based on the patient's reported side effects, although certain single nucleotide polymorphisms (SNPs) might alter treatment response and survival depending on the antifibrotic administered. This study investigated variations in response and outcomes to pirfenidone based on patients-specific genetic profiles.

Methods: Retrospective clinical data were collected from 56 IPF patients and had blood drawn for DNA extraction between 7/2013 and 3/2016, with the last patient followed until 10/2018. Nine SNPs were selected for pharmacogenetic investigation based on prior associations with IPF treatment outcomes or implications for pirfenidone metabolism. Genetic variants were examined in relation to clinical data and treatment outcomes.

Results: Of the 56 patients, 38 were males (67.85%). The average age of IPF at diagnosis was 66.88 years. At the initiation of pirfenidone, the average percent predicted FVC was 70.7%, and the average DLCO percent predicted was 50.02% (IQR 40-61%). Among the genetic variants tested, the TOLLIP rs5743890 risk allele was significantly associated with improved survival, with increasing pirfenidone duration. This finding was observed with CC or CT genotype carriers but not for those with the TT genotype (p = 0.0457). Similarly, the TGF-B1 rs1800470 risk allele was also significantly associated with improved survival with longer pirfenidone therapy (p = 0.0395), even though it was associated with disease progression.

Conclusion: This pilot study suggests that in IPF patients, the TOLLIP rs5743890 genotypes CC and CT, as well as TGF-B1 rs 1800470 may be associated with increased survival when treated with pirfenidone.

Keywords: Antifibrotic agents; Genotype; Idiopathic pulmonary fibrosis; Pharmacogenetics; Pirfenidone; Single nucleotide polymorphism.